Long-term safety and efficacy of patisiran for hereditary transthyretin-mediated amyloidosis with polyneuropathy: 12-month results of an open-label extension study

December 23rd, 2020|Categories: Clinical Development, immunostimulation, Pre-Clinical Research, Toxicology|

Adams D, Polydefkis M, GonzĂ¡lez-Duarte A, Wixner J, Kristen AV, Schmidt HH, Berk JL, Losada LĂ³pez IA, Dispenzieri A, Quan D, ConceiĂ§Ă£o IM, Slama MS, Gillmore JD, Kyriakides T, Ajroud-Driss S, Waddington-Cruz M, Mezei MM, PlantĂ©-Bordeneuve V, Attarian S, Mauricio E, Brannagan TH 3rd, Ueda ...

Go to Top